Should involved-field radiation therapy be used as an adjunct to lymphoma autotransplantation?

Bone Marrow Transplantation

Volumn 29, Issue 3, 2002, Pages 183-189

  Wadhwa, P ^a   Shina, D C ^b   Schenkein, D ^c,d   Lazarus, H M ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^c TUFTS MEDICAL CENTER   (United States)

^d MILLENNIUM PHARMACEUTICALS INC   (United States)

Author keywords

Autotransplantation; Involved field radiation therapy; Lymphoma

Indexed keywords

ALKYLATING AGENT; ANTINEOPLASTIC AGENT; BLEOMYCIN; BUSULFAN; CARMUSTINE; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; EPRATUZUMAB; ETOPOSIDE; HLL2; IBRITUMOMAB TIUXETAN; MELPHALAN; MONOCLONAL ANTIBODY LYM 1; PREDNISONE; RITUXIMAB; THIOTEPA; TOSITUMOMAB I 131; VINCRISTINE;

ADULT; AUTOLOGOUS BONE MARROW TRANSPLANTATION; BLOOD TOXICITY; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CANCER RESISTANCE; CONTROLLED STUDY; DRUG MECHANISM; HIGH RISK POPULATION; HODGKIN DISEASE; HUMAN; MAJOR CLINICAL STUDY; MULTIMODALITY CANCER THERAPY; MYELODYSPLASIA; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; RADIATION DOSE; RADIATION INJURY; RADIATION PNEUMONIA; RADIOISOTOPE THERAPY; SHORT SURVEY; THROMBOCYTOPENIA; TREATMENT FAILURE; TUMOR VOLUME;

COMBINED MODALITY THERAPY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOMA; RADIOTHERAPY, ADJUVANT; RECURRENCE; SURVIVAL RATE; TRANSPLANTATION, AUTOLOGOUS;

EID: 85047700219     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1703367     Document Type: Article

References (35)

1. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin’s lymphoma
2. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma
3. Autologous transplantation for diffuse aggressive non-Hodgkin’s lymphoma in patients never achieving remission: A report from the Autologous Blood and Marrow Transplant Registry
4. High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin’s lymphoma
5. Chemotherapy of advanced Hodgkin’s disease with MOPP, ABVD, or MOPP alternating with ABVD
6. Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin’s disease after combination chemotherapy: The low probability for cure
7. Autotransplants for Hodgkin’s disease in first relapse or second remission: A report from the autologous blood and marrow transplant registry (ABMTR)
8. Autotransplants for Hodgkin’s disease in patients never achieving remission: A report from the Autologous Blood and Marrow Transplant Registry
9. Treatment of progressive Hodgkin’s disease with intensive chemoradiotherapy and autologous bone marrow transplantation
10. Treatment of localized aggressive lymphomas with combination chemotherapy followed by involved-field radiation therapy
11. An ECOG randomized phase III trial of CHOP vs. CHOP + radiotherapy (XRT) for intermediate grade early stage non-Hodgkin’s lymphoma
12. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin’s lymphoma
13. Adjuvant radiotherapy to sites of previous bulky disease in patients stage IV diffuse large cell lymphoma
14. Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin’s lymphoma: Final analysis of the prospective LNH87-2 protocol- A groupe d’Etude des lymphomes de l’Adulte study
15. Prolonged disease-free survival after autologous bone marrow transplantation in patients with non-Hodgkin’s lymphoma with a poor prognosis
16. Autotransplantation for relapsed or refractory non-Hodgkin’s lymphoma (NHL): Long-term follow-up and analysis of prognostic factors
17. High dose chemotherapy and stem cell rescue for aggressive non-Hodgkin’s lymphoma: Pattern of failure and implications for involved-field radiotherapy
18. High-dose chemoradiotherapy and autologous stem cell transplantation for patients with primary refractory aggressive non-Hodgkin’s lymphoma: An intention-to-treat analysis
19. The impact of external beam radiation therapy prior to autologous bone marrow transplantation in patients with non-Hodgkin’s lymphoma
20. High-dose therapy and autologous bone marrow transplantation for relapsed/refractory Hodgkin’s disease: The impact of involved field radiotherapy on patterns of failure and survival
21. Patterns of failure following high-dose chemotherapy and autologous bone marrow transplantation with involved field radiotherapy for relapsed/refractory Hodgkin’s disease
22. Autotransplantation for relapsed or refractory Hodgkin’s disease: Long-term follow-up and analysis of prognostic factors
23. Thoracic radiation therapy before autologous bone marrow transplantation in relapsed or refractory Hodgkin’s disease
24. Involved field radiation post autologous stem cell transplantation in lymphoma patients is associated with major haematological toxicities
25. Predictors of therapy-related leukemia and myelodysplasia following autologous transplantation for lymphoma: An assessment of risk factors
26. Myelodysplastic syndrome as a late complication following autologous bone marrow transplantation for non-Hodgkin’s lymphoma
27. Autologous stem cell transplantation for non-Hodgkin’s lymphoma: Comparison of radiation-based and chemotherapy-only preparative regimens
28. The role of radiolabeled antibodies in the treatment of non-Hodgkin’s lymphoma: The coming of age of radioimmunotherapy
29. Principles of radioimmunotherapy for hematologists and oncologists
30. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin’s lymphoma
31. Radioimmunotherapy for patients with relapsed B-cell non-Hodgkin lymphoma
32. Radioimmunotherapy with iodine (131)I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: Updated results and long-term follow-up of the University of Michigan experience
33. Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin’s lymphomas
34. Phase I trial combining 90Y Zevalin and high-dose BEAM chemotherapy with hematopoietic cell transplant in relapsed or refractory B-cell NHL
35. A phase I/II trial of iodine131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas